Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
IRVINE, Calif., Aug. 22, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (Nasdaq:IPCI). Investors who purchased or otherwise acquired shares from January 14, 2016 through July 26, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 29, 2017 lead plaintiff motion deadline.
If you purchased IntelliPharmaCeutics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its New Drug Application (“NDA”) for Rexista; that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On July 24, 2017, scientists from the Food & Drug Administration (“FDA”) expressed concerns that the Company failed to provide enough data about the abuse potential of its opioid painkilling drug, Rexista. On July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s New Drug Application for Rexista, citing insufficient data regarding the abuse-deterrent properties of the drug as a motivating concern. Upon release of this news, the Company’s share price lowered materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
